Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
McKinsey
Merck
Harvard Business School
McKesson
Baxter

Last Updated: October 21, 2019

DrugPatentWatch Database Preview

Details for Patent: 8,193,182

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,193,182 protect, and when does it expire?

Patent 8,193,182 protects COPIKTRA and is included in one NDA.

This patent has ninety-five patent family members in twenty-six countries.

Summary for Patent: 8,193,182
Title:Substituted isoquinolin-1(2H)-ones, and methods of use thereof
Abstract: Chemical entities of Formula I: ##STR00001## that modulate PI3 kinase activity, pharmaceutical compositions containing the chemical entities, and methods of using these chemical entities for treating diseases and conditions associated with P13 kinase activity are described herein.
Inventor(s): Ren; Pingda (San Diego, CA), Liu; Yi (San Diego, CA), Wilson; Troy Edward (San Marino, CA), Li; Liansheng (San Diego, CA), Chan; Katrina (San Diego, CA), Rommel; Christian (La Jolla, CA)
Assignee: Intellikine, Inc. (La Jolla, CA)
Application Number:12/503,776
Patent Claim Types:
see list of patent claims
 

Drugs Protected by US Patent 8,193,182

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Verastem Inc COPIKTRA duvelisib CAPSULE;ORAL 211155-001 Sep 24, 2018 RX Yes No   Start Trial   Start Trial Y   Start Trial
Verastem Inc COPIKTRA duvelisib CAPSULE;ORAL 211155-002 Sep 24, 2018 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,193,182

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2009204483   Start Trial
Australia 2009204487   Start Trial
Australia 2010274075   Start Trial
Brazil 112012000968   Start Trial
Brazil PI0906473   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
McKesson
Colorcon
Harvard Business School
Baxter
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.